INDIA RUSSIA COLLABORATION REGARDING COVID-19 VACCINE SPUTNIK V
                     INDIA RUSSIA COLLABORATION REGARDING 
COVID-19 VACCINE SPUTNIK V
INTRODUCTION
• India is in touch with Russia over the 
Sputnik V Covid-19 vaccine, which was 
launched by Russian president Vladimir 
Putin on August 11.
Source: Times Now
COMMUNICATION
• As far as Sputnik-5 vaccine is concerned, 
India and Russia are in communication. 
• Some initial information has been 
shared by the government.
Source: India.com
WORLD'S FIRST COVID-19 VACCINE
• Russia had recently registered world's 
first Covid-19 vaccine.
• It is now in the phase III trial of the 
vaccine, which involved more than 
40,000 people at over 45 medical 
centres around Russia.
Source: The Financial Express
INDIA COVID-19 SITUATION
• India’s mortality rate has reduced to an 
all-time low of 1.58% and active cases 
are only 22.2 per cent of the total cases.
• The recovered cases are 3.4 times more 
than the active cases and the recovery 
rate is more than 75 per cent.
Source: Zee News
 COVID-19 SAMPLE TESTS IN INDIA
• As of August 25, 3.68 crore sample tests 
were conducted in the country.
• As of now the total cases in India has 
reached to 3.6million.
Source: Indian Express
 COVID-19 POSITIVE RATES IN INDIA
• The positive case percentage on the 
basis of a seven-day rolling average was 
11% in the first week of August which 
has now come down to 8%.
• While the number of tests has increased 
exponentially, there is a steady decline in 
Covid-19 positivity rate.
Source: The Hindu
 SPUTNIK V
• Russia has expressed its willingness to 
the Indian government for collaboration 
in the manufacturing of COVID vaccine - 
Sputnik V.
• Russia claims to have developed the 
first COVID-19 vaccine Sputnik V, a 
human adenoviral vector vaccine. 
Source: Times Now
 CLINICAL STUDY
• More than 40,000 people in 45 medical 
centres are participating in a clinical 
study of the Sputnik V vaccine in Russia.
• This clinical study also included with the 
vaccination of volunteers from risk 
groups.
Source: Tass
 JOINT VENTURE PLAN
• Production of the vaccine is an 
important issue and Russia is looking to 
Indian drug producers to co-partner.
•  As India is capable of producing 
Gamaleya Institute vaccine, the 
partnerships will produce a vaccine that 
enable to cover the demand.
Source: The Logical India
 UPDATE OF SPUTNIK V
• Phase 1 and 2 clinical trials of the 
vaccine have been completed on 
August.
• All the volunteers are feeling well, no 
unforeseen side effects were observed. 
• The vaccine-induced strong antibody 
and cellular immune response.
Source: Business Standard